Artículo
Fabry pedigree analysis: A successful program for targeted genetic approach
Rozenfeld, Paula Adriana
; Masllorens, Francisca M.; Roa, Norma; Rodriguez, Fernanda; Bonnano, Mariela; Yvorra, Carolina; Ceci, Romina
Fecha de publicación:
07/2019
Editorial:
John Wiley & Sons Inc.
Revista:
Molecular Genetics & Genomic Medicine
ISSN:
2324-9269
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Background: Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA). FD is still an underdiagnosed disorder worldwide. Moreover, there is delay between symptom onset and Fabry diagnosis of at least 10 years. Family screening offers an important benefit for detection of new patients. The aim of this work is to present the approach along with the results of a targeted genetic strategy for pedigree analysis for FD in Argentina. Methods: By this strategy as soon as a new index Fabry patient is diagnosed, the pedigree group contacts the physician and a meeting is arranged with the physician and the family to build the family tree. Results: Pedigree analysis was carried out for full in 31 families. In the work period, we have tested 1,462 relatives, and 501 were diagnosed FD. The proportion of positive detection was 33%. Conclusion: The targeted family screening approach is successful to detect undiagnosed Fabry patients. By this approach, the highest ratio index to pedigree ever reported for FD pedigree analysis of 1:15 was obtained.
Palabras clave:
DIAGNOSIS
,
FABRY DISEASE
,
FAMILY TREE
,
PEDIGREE
,
X-LINKED
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IIFP)
Articulos de INST. DE ESTUDIOS INMUNOLOGICOS Y FISIOPATOLOGICOS
Articulos de INST. DE ESTUDIOS INMUNOLOGICOS Y FISIOPATOLOGICOS
Citación
Rozenfeld, Paula Adriana; Masllorens, Francisca M.; Roa, Norma; Rodriguez, Fernanda; Bonnano, Mariela; et al.; Fabry pedigree analysis: A successful program for targeted genetic approach; John Wiley & Sons Inc.; Molecular Genetics & Genomic Medicine; 7; 7; 7-2019; 1-4
Compartir
Altmétricas